logo
What to know about ataxia telangiectasia

What to know about ataxia telangiectasia

Medical News Today16 hours ago
Ataxia telangiectasia (AT) is a rare genetic condition that people inherit from their parents. AT affects the part of the brain that controls movement and coordination. Ataxia is when a person has difficulty controlling their voluntary muscle movements. This can lead to difficulty with balance, coordination, speech, and fine motor tasks such as writing, typing, and buttoning clothing.Telangiectasia refers to tiny, spider-like blood vessels under the skin that have become widened or broken and are now visible. These blood vessels are typically more visible around the nose, cheeks, chin, legs, chest, and hands.AT describes when a person experiences a combination of ataxia and telangiectasia. This article discusses AT further, including a more detailed look into the causes, symptoms, diagnosis, treatment, and potential outlook for this condition.CausesThe ataxia-telangiectasia mutated (ATM) gene is responsible for creating the ATM protein. This protein plays a critical role in detecting DNA damage, repairing DNA, signaling cells to stop dividing while under repair, and shutting down cells with extensive damage.Mutations in the ATM gene can occur, which can change how the cells work or prevent them from working at all. AT can occur when a person inherits one mutation of the ATM gene from each parent. Healthcare professionals typically describe this pattern of inheritance as autosomal recessive.An article from 2023 suggests that if both parents carry one copy of the ATM gene mutation, a child may have a:25% chance of developing AT50% chance of carrying the ATM gene mutation but not developing AT25% chance of inheriting two working copies of the geneA person who carries only one copy of the gene mutation will not typically experience any symptoms of AT. However, it is possible that any children they may have will inherit the gene mutation, and they are more likely to develop cancer. »Learn more:Autosomal inheritance: Definition, types, and conditionsSymptomsAT typically appears in early childhood, often before 5 years of age. AT typically affects the nervous system, immune system, and the spine, which can lead to a number of symptoms, including:Movement and coordination issues: Children with AT can experience unsteady walking, a lack of balance, and difficulty coordinating movements.Difficulties with speech: As AT progresses, a person may experience slurred speech and difficulty swallowing.Issues with eye movements: An individual with AT may experience difficulty coordinating eye movements, or oculomotor apraxia.Skin changes: A person with AT may experience small, blue, red, or purple spider-like blood vessels around the eyes, cheeks, and ears. Immune system issues: People with AT may have a weakened immune system, which can increase the risk of infections, particularly in the lungs and sinuses.Other physical changes: A person with AT may experience other symptoms such as premature graying of the hair, fatigue, and delayed physical and sexual development.Additionally, research from 2019 suggests that a child with an immune deficiency, such as AT, may be more at risk of developing cancer. The most common types of cancer related to AT are acute lymphocytic leukemia and lymphoma.DiagnosisTo diagnose AT, a healthcare professional may assess symptoms, take a full medical history, and perform several tests. A healthcare professional will typically look for early symptoms, such as difficulty with balance and coordination, and blood vessels appearing on the skin and eyes.There are several tests a healthcare professional may use to diagnose AT, including:blood tests to detect low levels of certain immune cells and antibodiesgenetic testing to confirm whether a person carries both copies of the ATM gene mutationimaging scans, such as an MRI, to assess any damage to the part of the brain that controls coordination and movementeye tests to assess the movement of the eyesTreatmentResearch is ongoing to find new treatments that target the underlying causes of AT. However, there is currently no cure for AT or a way to slow down the speed at which the condition progresses. However, a healthcare professional can help a person manage symptoms and improve overall quality of life in several ways. For example: Physical therapy may help a person maintain flexibility, balance, and coordination for as long as possible.Speech therapy may help a person address difficulties with breathing, speaking, and swallowing. Boosting the immune system with nutrition, high doses of vitamins, antioxidants, and gamma-globulin injections.OutlookAs AT is a progressive condition, symptoms typically worsen over time. This can affect mobility, coordination, and the immune system. By the time a person reaches adolescence, they may require mobility aids, such as a wheelchair.A person with AT will typically experience a weakening of the immune system, which can increase the chances of developing infections. Therefore, a healthcare professional may regularly monitor people with AT to check for signs of infection.People with AT may also be more at risk of developing certain types of cancer. A healthcare professional will typically perform regular screenings so that they can start any necessary treatment early.The severity of the ATM gene mutation can influence a person's life expectancy. Typically, people with AT live into early adulthood.However, individual outlooks can vary depending on a person's overall health and other factors. For example, an individual with a later onset and slower progression of AT may live until they are approximately 50 to 60 years old. A person should contact a healthcare professional to learn more about their individual outlook.SummaryAT is a rare, genetic condition that can occur when a person inherits one ATM gene mutation from each parent. AT typically affects balance, coordination, the nervous system, the immune system, and the spine. Symptoms can include difficulty with movement, issues with speech, trouble swallowing, and small visible blood vessels on the skin and eyes. A healthcare professional will typically diagnose AT by assessing symptoms, taking a full medical history, and performing several tests. There is currently no cure for AT. However, management options such as physical therapy, speech therapy, and immune system support can improve overall quality of life.People should contact a healthcare professional if they or a child in their care is experiencing symptoms that may indicate AT. A doctor can make an accurate diagnosis and recommend appropriate treatment, if necessary.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US senators Wyden and Warren launch investigation into UnitedHealth over alleged nursing home payments
US senators Wyden and Warren launch investigation into UnitedHealth over alleged nursing home payments

Reuters

time26 minutes ago

  • Reuters

US senators Wyden and Warren launch investigation into UnitedHealth over alleged nursing home payments

Aug 7 (Reuters) - Senators Ron Wyden and Elizabeth Warren are launching an investigation into UnitedHealth Group (UNH.N), opens new tab related to allegations that the healthcare conglomerate secretly paid nursing homes thousands in bonuses to help slash hospital transfers for ailing residents. In a letter dated August 6 to UnitedHealth CEO Stephen Hemsley, the senators called on the company to provide detailed information about its reported incentive programming and its impact on residents. The senators have sought responses by September 8. In May, the UK's Guardian newspaper reported the company made secret payments to nursing homes, as part of a series of cost-cutting tactics, that saved the company millions, but at times risked residents' health, citing an investigation carried out by the newspaper. At that time, UnitedHealth had said the U.S. Department of Justice had investigated those allegations, interviewed witnesses, and obtained thousands of documents that demonstrated the significant factual inaccuracies in the allegations.

Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters
Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

Reuters

time26 minutes ago

  • Reuters

Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

NEW YORK, Aug 7 (Reuters) - Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some investors are betting that the beaten-down shares are now becoming too much of a bargain to pass up. The S&P 500 healthcare sector (.SPXHC), opens new tab -- which includes pharmaceutical companies, biotechs, health insurers and medical equipment makers -- has slumped 5% in 2025, lagging the over 7% gain for the overall index (.SPX), opens new tab. Pressure to bring down U.S. prescription drug prices to overseas rates, tariffs targeted at pharmaceuticals and cuts to areas such as health research funding and Medicaid are among the Trump administration actions clouding the outlook for the shares this year, investors said. Regulatory obstacles are compounding issues, including expiring drug patents and setbacks for bellwethers including UnitedHealth Group (UNH.N), opens new tab. "You have got this constant overarching political and regulatory overhang that doesn't really seem to subside with any administration," said Jared Holz, healthcare sector strategist at Mizuho Securities. "When you have so much nebulousness around the sector, it turns people off rather than invites them to the party." In another sign of the group losing favor, healthcare exchange-traded-funds have seen 12 consecutive months of net outflows as of July for a total outflow of $11.5 billion in that time, more than for any other sector, according to State Street Investment Management. The performance picture is even dimmer over a longer period. While shares of massive technology companies pushed the benchmark S&P 500 up over 50% the past three years, the healthcare sector is little changed in that time. That gap has put the 60-stock sector at nearly its biggest discount to the broader market in 30 years, which some investors hope is an inflection point for the battered group. "The valuation is extremely cheap and the relative performance is at an extreme," said Walter Todd, chief investment officer at Greenwood Capital, whose healthcare holdings include diversified giant Johnson & Johnson (JNJ.N), opens new tab and medical device maker Stryker (SYK.N), opens new tab. "So at this point, it seems like a pretty decent setup to get some outperformance." The price-to-earnings ratio for the healthcare sector, based on earnings estimates for the next year, has fallen to 16.2 times from nearly 20 a year ago, according to LSEG Datastream. Meanwhile, the S&P 500's rally to records has driven the index's P/E ratio to over 22 times -- giving the broader market a significant premium over the healthcare sector. Some high-profile healthcare names are at even cheaper valuations. For example, Merck (MRK.N), opens new tab is trading at a forward P/E of 8.7, against its long-term average of 14.5, while fellow drugmaker Bristol Myers Squibb (BMY.N), opens new tab trades at 7.4 against its average of 15.8, according to LSEG. Year-to-date, shares of both Merck and Bristol Myers are down roughly 20%. The group is drawing bets from some value investors such as Patrick Kaser, portfolio manager at Brandywine Global, whose portfolio is overweight the sector including owning shares of CVS Health (CVS.N), opens new tab and European drugmakers GSK (GSK.L), opens new tab and Sanofi ( opens new tab. "Our perspective is a lot of this bad news is priced in and then some," Kaser said. "To bet against the sector from here, you're essentially continuing to bet on the valuation gap, which is already large, continuing to widen." The group's decline means the total market value of the S&P 500 healthcare sector is about $4.8 trillion, not much higher than the $4.3 trillion value of Nvidia (NVDA.O), opens new tab, the semiconductor company that has symbolized the artificial intelligence boom. Indeed, some investors said a shift in capital away from Nvidia and other massive tech companies could spark healthcare shares. Such a move appeared to occur in the first quarter, investors said, when the healthcare sector rose 6% while declines in tech and megacap stocks dragged indexes lower. Fears of an economic downturn also could help healthcare shares, at least on a relative basis. The group is often viewed as a defensive area in rockier economic times. Economic fears flared following last Friday's weaker-than-expected employment report, while some strategists say the market could be due for a pullback after surging over 20% since its April lows. "During the first quarter, healthcare did great even as tech rolled over, as the fears of an economic slowdown got to more economically sensitive stocks," said Chris Grisanti, chief market strategist at MAI Capital Management, adding he expects healthcare "will perform better in a more difficult market." More clarity on regulatory issues, including tariffs, also could support healthcare, investors said. But some value investors are hesitant to dive into the group. Michael Mullaney, director of global markets research at Boston Partners, said he is wary some healthcare shares could be "value traps," preferring to overweight areas including industrials or financials. "There's been just so much of an overhang in the sector," Mullaney said. "There are better places to go with cleaner stories."

Study shows genes contribute to chance of developing debilitating disease
Study shows genes contribute to chance of developing debilitating disease

The Independent

timean hour ago

  • The Independent

Study shows genes contribute to chance of developing debilitating disease

A new study, DecodeME, has found significant DNA differences in people with ME / chronic fatigue syndrome (CFS), offering the first robust evidence that genes contribute to developing the serious disease. Researchers identified eight distinct areas of genetic code in ME/CFS patients that are markedly different from those without the condition, primarily involving genes linked to the immune and nervous systems. At least two of the genetic signals relate to how the body responds to infection, aligning with long-standing patient reports that the onset of ME/CFS symptoms often follows an infectious illness. The findings are expected to boost credibility for ME/CFS patients, helping to rebuff the stigma and lack of belief often associated with the condition. The DecodeME study, described as the world's largest of its kind, analysed DNA samples from over 15,000 participants. The key genetic difference ME sufferers have from others – and what it means

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store